Acomplia (Rimonabant)

Acomplia (Rimonabant)

Manufacturer: Sanofi-Aventis

Acomplia (rimobant) is a weight-loss medicine. It is marketed under the brand names Acomplia in Europe and Zimulti in the USA. There is also a generic version of this drug called Rimonabant. Although Acomplia has been approved for marketing throughout Europe, it is still undergoing the process of approval in other countries. Therefore the best way of buying Acomplia is through online pharmacies.

What is it?

Acomplia belongs to the new class of therapeutic agents known as Cannabinoid-1 (CB1) Receptor Blockers. It is used to treat obesity, overweight and related conditions.

How does it work?

Acomplia selectively blocks CB1 receptors of brain and peripheral organs that account for glucose and fat metabolism. It switches off brain circuits that cause the feeling of hunger. By blocking CB1 receptors Acomplia slows down the activity of endocannabinoid system or EC for short. EC system regulates body weight and controls energy balance.

What is it used for?

Accomplia is used as a supplement to diet and exercise for the patients with obesity and overweight suffering from Type 2 diabetes and excessive level of fat in blood.

The manufacturer also claims that Acomplia can decrease the risk of cardiovascular disease.

Can it help to Quit smoking?

According to researches conducted by Sanofi-Aventis Company Acomplia can be used as an aid to smoking cessation but a relevant approvable letter from the FDA has yet to be issued.

What did clinical trial studies of Acomplia show?

The results of clinical studies proved that Acomplia improves a wide range of cardiometabolic risk factors and promotes sustainable Weight Loss. Nearly half of the improvements that were observed in patients receiving 20mg of Acomplia can’t be accounted for by Weight Loss alone.

What are the side-effects?

19% of patients receiving Acomplia vs 13% of those taking placebo experienced vomiting and nausea and were forced to leave the trial.